TARA – protara therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology [Yahoo! Finance]
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
Protara Therapeutics, Inc. (NASDAQ: TARA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Form SC 13G Protara Therapeutics, Filed by: Opaleye Management Inc.
Form SC 13G Protara Therapeutics, Filed by: Woodline Partners LP
Form SC 13G/A Protara Therapeutics, Filed by: CVI Investments, Inc.
Form 8-K Protara Therapeutics, For: Nov 12
Form 10-Q Protara Therapeutics, For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.